Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 62

1.

ProTide generated long-acting abacavir nanoformulations.

Lin Z, Gautam N, Alnouti Y, McMillan J, Bade AN, Gendelman HE, Edagwa B.

Chem Commun (Camb). 2018 Jul 11. doi: 10.1039/c8cc04708a. [Epub ahead of print]

PMID:
29995046
2.

Species differences in bile acids II. Bile acid metabolism.

Thakare R, Alamoudi JA, Gautam N, Rodrigues AD, Alnouti Y.

J Appl Toxicol. 2018 May 29. doi: 10.1002/jat.3645. [Epub ahead of print]

PMID:
29845631
3.

Species differences in bile acids I. Plasma and urine bile acid composition.

Thakare R, Alamoudi JA, Gautam N, Rodrigues AD, Alnouti Y.

J Appl Toxicol. 2018 May 21. doi: 10.1002/jat.3644. [Epub ahead of print]

PMID:
29785833
4.

Optimizing the preparation and stability of decorated antiretroviral drug nanocrystals.

Zhou T, Lin Z, Puligujja P, Palandri D, Hilaire J, Araínga M, Smith N, Gautam N, McMillan J, Alnouti Y, Liu X, Edagwa B, Gendelman HE.

Nanomedicine (Lond). 2018 Apr;13(8):871-885. doi: 10.2217/nnm-2017-0381. Epub 2018 Mar 19.

5.

Simultaneous quantification of intracellular lamivudine and abacavir triphosphate metabolites by LC-MS/MS.

Gautam N, Lin Z, Banoub MG, Smith NA, Maayah A, McMillan J, Gendelman HE, Alnouti Y.

J Pharm Biomed Anal. 2018 May 10;153:248-259. doi: 10.1016/j.jpba.2018.02.036. Epub 2018 Feb 20.

PMID:
29518644
6.

Creation of a long-acting nanoformulated dolutegravir.

Sillman B, Bade AN, Dash PK, Bhargavan B, Kocher T, Mathews S, Su H, Kanmogne GD, Poluektova LY, Gorantla S, McMillan J, Gautam N, Alnouti Y, Edagwa B, Gendelman HE.

Nat Commun. 2018 Feb 6;9(1):443. doi: 10.1038/s41467-018-02885-x.

7.

Modulation of the intestinal bile acid/farnesoid X receptor/fibroblast growth factor 15 axis improves alcoholic liver disease in mice.

Hartmann P, Hochrath K, Horvath A, Chen P, Seebauer CT, Llorente C, Wang L, Alnouti Y, Fouts DE, Stärkel P, Loomba R, Coulter S, Liddle C, Yu RT, Ling L, Rossi SJ, DePaoli AM, Downes M, Evans RM, Brenner DA, Schnabl B.

Hepatology. 2018 Jun;67(6):2150-2166. doi: 10.1002/hep.29676. Epub 2018 Apr 16.

PMID:
29159825
8.

Pharmacokinetics of a Long-Acting Nanoformulated Dolutegravir Prodrug in Rhesus Macaques.

McMillan J, Szlachetka A, Slack L, Sillman B, Lamberty B, Morsey B, Callen S, Gautam N, Alnouti Y, Edagwa B, Gendelman HE, Fox HS.

Antimicrob Agents Chemother. 2017 Dec 21;62(1). pii: e01316-17. doi: 10.1128/AAC.01316-17. Print 2018 Jan.

9.

Creation of a nanoformulated cabotegravir prodrug with improved antiretroviral profiles.

Zhou T, Su H, Dash P, Lin Z, Dyavar Shetty BL, Kocher T, Szlachetka A, Lamberty B, Fox HS, Poluektova L, Gorantla S, McMillan J, Gautam N, Mosley RL, Alnouti Y, Edagwa B, Gendelman HE.

Biomaterials. 2018 Jan;151:53-65. doi: 10.1016/j.biomaterials.2017.10.023. Epub 2017 Oct 15.

10.

Harmonizing lipidomics: NIST interlaboratory comparison exercise for lipidomics using SRM 1950-Metabolites in Frozen Human Plasma.

Bowden JA, Heckert A, Ulmer CZ, Jones CM, Koelmel JP, Abdullah L, Ahonen L, Alnouti Y, Armando AM, Asara JM, Bamba T, Barr JR, Bergquist J, Borchers CH, Brandsma J, Breitkopf SB, Cajka T, Cazenave-Gassiot A, Checa A, Cinel MA, Colas RA, Cremers S, Dennis EA, Evans JE, Fauland A, Fiehn O, Gardner MS, Garrett TJ, Gotlinger KH, Han J, Huang Y, Neo AH, Hyötyläinen T, Izumi Y, Jiang H, Jiang H, Jiang J, Kachman M, Kiyonami R, Klavins K, Klose C, Köfeler HC, Kolmert J, Koal T, Koster G, Kuklenyik Z, Kurland IJ, Leadley M, Lin K, Maddipati KR, McDougall D, Meikle PJ, Mellett NA, Monnin C, Moseley MA, Nandakumar R, Oresic M, Patterson R, Peake D, Pierce JS, Post M, Postle AD, Pugh R, Qiu Y, Quehenberger O, Ramrup P, Rees J, Rembiesa B, Reynaud D, Roth MR, Sales S, Schuhmann K, Schwartzman ML, Serhan CN, Shevchenko A, Somerville SE, St John-Williams L, Surma MA, Takeda H, Thakare R, Thompson JW, Torta F, Triebl A, Trötzmüller M, Ubhayasekera SJK, Vuckovic D, Weir JM, Welti R, Wenk MR, Wheelock CE, Yao L, Yuan M, Zhao XH, Zhou S.

J Lipid Res. 2017 Dec;58(12):2275-2288. doi: 10.1194/jlr.M079012. Epub 2017 Oct 6.

PMID:
28986437
11.

Simultaneous LC-MS/MS analysis of eicosanoids and related metabolites in human serum, sputum and BALF.

Thakare R, Chhonker YS, Gautam N, Nelson A, Casaburi R, Criner G, Dransfield MT, Make B, Schmid KK, Rennard SI, Alnouti Y.

Biomed Chromatogr. 2018 Mar;32(3). doi: 10.1002/bmc.4102. Epub 2017 Oct 17.

12.

Increased glycine-amidated hyocholic acid correlates to improved early weight loss after sleeve gastrectomy.

Kindel TL, Krause C, Helm MC, McBride CL, Oleynikov D, Thakare R, Alamoudi J, Kothari V, Alnouti Y, Kohli R.

Surg Endosc. 2018 Feb;32(2):805-812. doi: 10.1007/s00464-017-5747-y. Epub 2017 Aug 4.

PMID:
28779240
13.

Leveraging of Rifampicin-Dosed Cynomolgus Monkeys to Identify Bile Acid 3-O-Sulfate Conjugates as Potential Novel Biomarkers for Organic Anion-Transporting Polypeptides.

Thakare R, Gao H, Kosa RE, Bi YA, Varma MVS, Cerny MA, Sharma R, Kuhn M, Huang B, Liu Y, Yu A, Walker GS, Niosi M, Tremaine L, Alnouti Y, Rodrigues AD.

Drug Metab Dispos. 2017 Jul;45(7):721-733. doi: 10.1124/dmd.117.075275. Epub 2017 Apr 10.

14.

Pharmacokinetic and Biodistribution Studies of HPMA Copolymer Conjugates in an Aseptic Implant Loosening Mouse Model.

Wei X, Li F, Zhao G, Chhonker YS, Averill C, Galdamez J, Purdue PE, Wang X, Fehringer EV, Garvin KL, Goldring SR, Alnouti Y, Wang D.

Mol Pharm. 2017 May 1;14(5):1418-1428. doi: 10.1021/acs.molpharmaceut.7b00045. Epub 2017 Apr 5.

15.

A combination of dietary N-3 fatty acids and a cyclooxygenase-1 inhibitor attenuates nonalcoholic fatty liver disease in mice.

Saraswathi V, Perriotte-Olson C, Ganesan M, Desouza CV, Alnouti Y, Duryee MJ, Thiele GM, Nordgren TM, Clemens DL.

J Nutr Biochem. 2017 Apr;42:149-159. doi: 10.1016/j.jnutbio.2017.01.011. Epub 2017 Jan 27.

PMID:
28187366
16.

Autophagy facilitates macrophage depots of sustained-release nanoformulated antiretroviral drugs.

Gnanadhas DP, Dash PK, Sillman B, Bade AN, Lin Z, Palandri DL, Gautam N, Alnouti Y, Gelbard HA, McMillan J, Mosley RL, Edagwa B, Gendelman HE, Gorantla S.

J Clin Invest. 2017 Mar 1;127(3):857-873. doi: 10.1172/JCI90025. Epub 2017 Jan 30.

17.

Creation of a Long-Acting Nanoformulated 2',3'-Dideoxy-3'-Thiacytidine.

Guo D, Zhou T, Araínga M, Palandri D, Gautam N, Bronich T, Alnouti Y, McMillan J, Edagwa B, Gendelman HE.

J Acquir Immune Defic Syndr. 2017 Mar 1;74(3):e75-e83. doi: 10.1097/QAI.0000000000001170.

18.

Novel fluorinated pyrrolomycins as potent anti-staphylococcal biofilm agents: Design, synthesis, pharmacokinetics and antibacterial activities.

Yang Z, Liu Y, Ahn J, Qiao Z, Endres JL, Gautam N, Huang Y, Li J, Zheng J, Alnouti Y, Bayles KW, Li R.

Eur J Med Chem. 2016 Nov 29;124:129-137. doi: 10.1016/j.ejmech.2016.08.017. Epub 2016 Aug 12.

PMID:
27565555
19.

Development and characterization of a long-acting nanoformulated abacavir prodrug.

Singh D, McMillan J, Hilaire J, Gautam N, Palandri D, Alnouti Y, Gendelman HE, Edagwa B.

Nanomedicine (Lond). 2016 Aug;11(15):1913-27. doi: 10.2217/nnm-2016-0164. Epub 2016 Jul 26.

20.

Quantitative analysis of endogenous compounds.

Thakare R, Chhonker YS, Gautam N, Alamoudi JA, Alnouti Y.

J Pharm Biomed Anal. 2016 Sep 5;128:426-437. doi: 10.1016/j.jpba.2016.06.017. Epub 2016 Jun 11. Review.

PMID:
27344632
21.

Impaired synaptic development in a maternal immune activation mouse model of neurodevelopmental disorders.

Coiro P, Padmashri R, Suresh A, Spartz E, Pendyala G, Chou S, Jung Y, Meays B, Roy S, Gautam N, Alnouti Y, Li M, Dunaevsky A.

Brain Behav Immun. 2015 Nov;50:249-258. doi: 10.1016/j.bbi.2015.07.022. Epub 2015 Jul 26.

22.

Irreversible binding of an anticancer compound (BI-94) to plasma proteins.

Gautam N, Thakare R, Rana S, Natarajan A, Alnouti Y.

Xenobiotica. 2015;45(10):858-73. doi: 10.3109/00498254.2015.1025250. Epub 2015 Apr 14.

23.

A Major Human Oral Lysophosphatidic Acid Species, LPA 18:1, Regulates Novel Genes in Human Gingival Fibroblasts.

Cerutis DR, Weston MD, Alnouti Y, Bathena SP, Nunn ME, Ogunleye AO, McVaney TP, Headen KV, Miyamoto T.

J Periodontol. 2015 May;86(5):713-25. doi: 10.1902/jop.2015.140592. Epub 2015 Feb 9.

PMID:
25660500
24.

Urinary bile acids as biomarkers for liver diseases II. Signature profiles in patients.

Bathena SP, Thakare R, Gautam N, Mukherjee S, Olivera M, Meza J, Alnouti Y.

Toxicol Sci. 2015 Feb;143(2):308-18. doi: 10.1093/toxsci/kfu228. Epub 2014 Oct 24.

PMID:
25344563
25.

Urinary bile acids as biomarkers for liver diseases I. Stability of the baseline profile in healthy subjects.

Bathena SP, Thakare R, Gautam N, Mukherjee S, Olivera M, Meza J, Alnouti Y.

Toxicol Sci. 2015 Feb;143(2):296-307. doi: 10.1093/toxsci/kfu227. Epub 2014 Oct 24.

PMID:
25344562
26.

Pharmacokinetics, biodistribution, and toxicity of folic acid-coated antiretroviral nanoformulations.

Gautam N, Puligujja P, Balkundi S, Thakare R, Liu XM, Fox HS, McMillan J, Gendelman HE, Alnouti Y.

Antimicrob Agents Chemother. 2014 Dec;58(12):7510-9. doi: 10.1128/AAC.04108-14. Epub 2014 Oct 6.

27.

Nod2 deficiency protects mice from cholestatic liver disease by increasing renal excretion of bile acids.

Wang L, Hartmann P, Haimerl M, Bathena SP, Sjöwall C, Almer S, Alnouti Y, Hofmann AF, Schnabl B.

J Hepatol. 2014 Jun;60(6):1259-67. doi: 10.1016/j.jhep.2014.02.012. Epub 2014 Feb 19.

28.

The profile of bile acids and their sulfate metabolites in human urine and serum.

Bathena SP, Mukherjee S, Olivera M, Alnouti Y.

J Chromatogr B Analyt Technol Biomed Life Sci. 2013 Dec 30;942-943:53-62. doi: 10.1016/j.jchromb.2013.10.019. Epub 2013 Oct 22.

PMID:
24212143
29.

Combinatorial assessments of brain tissue metabolomics and histopathology in rodent models of human immunodeficiency virus infection.

Epstein AA, Narayanasamy P, Dash PK, High R, Bathena SP, Gorantla S, Poluektova LY, Alnouti Y, Gendelman HE, Boska MD.

J Neuroimmune Pharmacol. 2013 Dec;8(5):1224-38. doi: 10.1007/s11481-013-9461-9. Epub 2013 May 24.

30.

Preclinical pharmacokinetics and tissue distribution of long-acting nanoformulated antiretroviral therapy.

Gautam N, Roy U, Balkundi S, Puligujja P, Guo D, Smith N, Liu XM, Lamberty B, Morsey B, Fox HS, McMillan J, Gendelman HE, Alnouti Y.

Antimicrob Agents Chemother. 2013 Jul;57(7):3110-20. doi: 10.1128/AAC.00267-13. Epub 2013 Apr 22.

31.

Pharmacokinetics, protein binding and metabolism of a quinoxaline urea analog as an NF-κB inhibitor in mice and rats by LC-MS/MS.

Gautam N, Bathena SP, Chen Q, Natarajan A, Alnouti Y.

Biomed Chromatogr. 2013 Jul;27(7):900-9. doi: 10.1002/bmc.2880. Epub 2013 Mar 10.

32.

Targeting the NF-κB and mTOR pathways with a quinoxaline urea analog that inhibits IKKβ for pancreas cancer therapy.

Radhakrishnan P, Bryant VC, Blowers EC, Rajule RN, Gautam N, Anwar MM, Mohr AM, Grandgenett PM, Bunt SK, Arnst JL, Lele SM, Alnouti Y, Hollingsworth MA, Natarajan A.

Clin Cancer Res. 2013 Apr 15;19(8):2025-35. doi: 10.1158/1078-0432.CCR-12-2909. Epub 2013 Feb 26.

33.

Long-acting nanoformulated antiretroviral therapy elicits potent antiretroviral and neuroprotective responses in HIV-1-infected humanized mice.

Dash PK, Gendelman HE, Roy U, Balkundi S, Alnouti Y, Mosley RL, Gelbard HA, McMillan J, Gorantla S, Poluektova LY.

AIDS. 2012 Nov 13;26(17):2135-44. doi: 10.1097/QAD.0b013e328357f5ad.

34.

Pharmacodynamic and antiretroviral activities of combination nanoformulated antiretrovirals in HIV-1-infected human peripheral blood lymphocyte-reconstituted mice.

Roy U, McMillan J, Alnouti Y, Gautum N, Smith N, Balkundi S, Dash P, Gorantla S, Martinez-Skinner A, Meza J, Kanmogne G, Swindells S, Cohen SM, Mosley RL, Poluektova L, Gendelman HE.

J Infect Dis. 2012 Nov 15;206(10):1577-88. doi: 10.1093/infdis/jis395. Epub 2012 Jul 17.

35.

Cisplatin-loaded core cross-linked micelles: comparative pharmacokinetics, antitumor activity, and toxicity in mice.

Oberoi HS, Nukolova NV, Laquer FC, Poluektova LY, Huang J, Alnouti Y, Yokohira M, Arnold LL, Kabanov AV, Cohen SM, Bronich TK.

Int J Nanomedicine. 2012;7:2557-71. doi: 10.2147/IJN.S29145. Epub 2012 Jun 8.

36.

Mononuclear phagocyte intercellular crosstalk facilitates transmission of cell-targeted nanoformulated antiretroviral drugs to human brain endothelial cells.

Kanmogne GD, Singh S, Roy U, Liu X, McMillan J, Gorantla S, Balkundi S, Smith N, Alnouti Y, Gautam N, Zhou Y, Poluektova L, Kabanov A, Bronich T, Gendelman HE.

Int J Nanomedicine. 2012;7:2373-88. doi: 10.2147/IJN.S29454. Epub 2012 May 8.

37.

Rapid and reliable quantitation of amino acids and myo-inositol in mouse brain by high performance liquid chromatography and tandem mass spectrometry.

Bathena SP, Huang J, Epstein AA, Gendelman HE, Boska MD, Alnouti Y.

J Chromatogr B Analyt Technol Biomed Life Sci. 2012 Apr 15;893-894:15-20. doi: 10.1016/j.jchromb.2012.01.035. Epub 2012 Feb 28.

38.

Quantification of the transporter substrate fexofenadine in cell lysates by liquid chromatography/tandem mass spectrometry.

Flynn CA, Alnouti Y, Reed GA.

Rapid Commun Mass Spectrom. 2011 Aug 30;25(16):2361-6. doi: 10.1002/rcm.5111.

39.

UPLC-MS/MS quantification of nanoformulated ritonavir, indinavir, atazanavir, and efavirenz in mouse serum and tissues.

Huang J, Gautam N, Bathena SP, Roy U, McMillan J, Gendelman HE, Alnouti Y.

J Chromatogr B Analyt Technol Biomed Life Sci. 2011 Aug 1;879(23):2332-8. doi: 10.1016/j.jchromb.2011.06.032. Epub 2011 Jul 1.

40.

Quantitative determination of lysophosphatidic acids (LPAs) in human saliva and gingival crevicular fluid (GCF) by LC-MS/MS.

Bathena SP, Huang J, Nunn ME, Miyamoto T, Parrish LC, Lang MS, McVaney TP, Toews ML, Cerutis DR, Alnouti Y.

J Pharm Biomed Anal. 2011 Sep 10;56(2):402-7. doi: 10.1016/j.jpba.2011.05.041. Epub 2011 Jun 6.

41.

Buspirone, fexofenadine, and omeprazole: quantification of probe drugs and their metabolites in human plasma.

Gor P, Alnouti Y, Reed GA.

J Pharm Biomed Anal. 2011 Jul 15;55(5):1127-35. doi: 10.1016/j.jpba.2011.03.043. Epub 2011 Apr 9.

42.

Simultaneous characterization of bile acids and their sulfate metabolites in mouse liver, plasma, bile, and urine using LC-MS/MS.

Huang J, Bathena SP, Csanaky IL, Alnouti Y.

J Pharm Biomed Anal. 2011 Jul 15;55(5):1111-9. doi: 10.1016/j.jpba.2011.03.035. Epub 2011 Apr 6.

PMID:
21530128
43.

Mechanisms of gender-specific regulation of mouse sulfotransferases (Sults).

Alnouti Y, Klaassen CD.

Xenobiotica. 2011 Mar;41(3):187-97. doi: 10.3109/00498254.2010.535923. Epub 2010 Nov 23.

45.

Pharmacokinetic and biodistribution studies of N-(2-hydroxypropyl)methacrylamide copolymer-dexamethasone conjugates in adjuvant-induced arthritis rat model.

Quan LD, Yuan F, Liu XM, Huang JG, Alnouti Y, Wang D.

Mol Pharm. 2010 Aug 2;7(4):1041-9. doi: 10.1021/mp100132h.

46.

Praziquantel analogs with activity against juvenile Schistosoma mansoni.

Dong Y, Chollet J, Vargas M, Mansour NR, Bickle Q, Alnouti Y, Huang J, Keiser J, Vennerstrom JL.

Bioorg Med Chem Lett. 2010 Apr 15;20(8):2481-4. doi: 10.1016/j.bmcl.2010.03.001. Epub 2010 Mar 4.

PMID:
20303754
47.

Kinetic analysis of bile acid sulfation by stably expressed human sulfotransferase 2A1 (SULT2A1).

Huang J, Bathena SP, Tong J, Roth M, Hagenbuch B, Alnouti Y.

Xenobiotica. 2010 Mar;40(3):184-94. doi: 10.3109/00498250903514607.

PMID:
20102295
48.

Bile Acid sulfation: a pathway of bile acid elimination and detoxification.

Alnouti Y.

Toxicol Sci. 2009 Apr;108(2):225-46. doi: 10.1093/toxsci/kfn268. Epub 2009 Jan 8. Review.

PMID:
19131563
49.

Quantitative-profiling of bile acids and their conjugates in mouse liver, bile, plasma, and urine using LC-MS/MS.

Alnouti Y, Csanaky IL, Klaassen CD.

J Chromatogr B Analyt Technol Biomed Life Sci. 2008 Oct 1;873(2):209-17. doi: 10.1016/j.jchromb.2008.08.018. Epub 2008 Sep 3.

50.

Synthesis and evaluation of a well-defined HPMA copolymer-dexamethasone conjugate for effective treatment of rheumatoid arthritis.

Liu XM, Quan LD, Tian J, Alnouti Y, Fu K, Thiele GM, Wang D.

Pharm Res. 2008 Dec;25(12):2910-9. doi: 10.1007/s11095-008-9683-3. Epub 2008 Jul 23.

Supplemental Content

Loading ...
Support Center